Mineralys Therapeutics, Inc. filed a Form 8-K on November 4, 2026, disclosing the resignation of board director Derek DiRocco, Ph.D., and reporting financial results for the quarter ended September 30, 2026.

Key Highlights

  • Board resignation: Derek DiRocco, Ph.D. informed the Board of Directors on October 29, 2026 of his decision to resign, effective December 31, 2026.
  • No disagreement cited: According to the filing, Dr. DiRocco "advised the Company that his decision was not the result of any disagreement with the Company or its management on any matter relating to the Company's operations, policies, or practices."
  • Quarterly results announced: On November 4, 2026, the company issued a press release reporting financial results for the quarter ended September 30, 2026.
  • Emerging growth company: The filing identifies Mineralys Therapeutics, Inc. as an emerging growth company as defined under applicable securities regulations.
  • Exchange listing: The company's common stock, par value $0.0001 per share, trades on NASDAQ:MLYS.

Mineralys Therapeutics Discloses Board Change and Q3 2026 Results

Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a Delaware-incorporated biopharmaceutical company headquartered in Radnor, Pennsylvania, filed a current report on November 4, 2026, covering two separate disclosure items. The company disclosed that Derek DiRocco, Ph.D. notified the Board of Directors on October 29, 2026 of his resignation from the Board, with his departure set to take effect on December 31, 2026. The filing states that Dr. DiRocco's decision was not related to any disagreement with the company or its management.

Separately, also on November 4, 2026, the company issued a press release announcing financial results for the quarter ended September 30, 2026, along with a corporate update. That press release is attached to the filing as Exhibit 99.1. The filing notes, in accordance with General Instruction B.2 of Form 8-K, that the financial results information in Item 2.02 and the accompanying exhibit "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934." No specific financial figures from the press release are reproduced in the body of the 8-K itself.

The report was signed by Jeffrey A. Munsie, Chief Legal Officer and Secretary of Mineralys Therapeutics, Inc., on November 4, 2026. The company has indicated it has not elected to use the extended transition period for complying with new or revised financial accounting standards, as an emerging growth company.

What Was Disclosed

The 8-K reported the planned December 31, 2026 resignation of board member Derek DiRocco, Ph.D., citing no disagreement with management, and announced the availability of the company's Q3 2026 financial results via an attached press release.